Robert Glanzman
Keine laufenden Positionen mehr
Profil
Robert Glanzman worked as a Senior Medical Director at Pfizer AG, Director-Clinical Research at Purdue Pharmaceuticals LP, Vice President-Clinical Development at Nektar Therapeutics, and Assistant Clinical Professor at the University of Michigan.
He also served as the Chief Medical Officer at GeNeuro SA (Switzerland) from 2015 to 2019 and is currently the Chief Medical Officer at Clene, Inc. Dr. Glanzman earned his doctorate degree from Wake Forest School of Medicine in 1987 and his undergraduate degree from The University of North Carolina at Charlotte in 1982.
Ehemalige bekannte Positionen von Robert Glanzman
| Unternehmen | Position | Ende |
|---|---|---|
| CLENE INC. | Chief Tech/Sci/R&D Officer | 01.04.2023 |
| GENEURO SA | Chief Tech/Sci/R&D Officer | 30.06.2019 |
| University of Michigan | Corporate Officer/Principal | - |
| Pfizer AG | Chief Tech/Sci/R&D Officer | - |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | - |
Ausbildung von Robert Glanzman
| Wake Forest School of Medicine | Doctorate Degree |
| The University of North Carolina at Charlotte | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| GENEURO SA | Health Technology |
| CLENE INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Pfizer AG | |
Purdue Pharmaceuticals LP
 Purdue Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Purdue Pharmaceuticals LP is a physician-founded and physician-led company that develops, manufactures, and markets medications and consumer health products. Purdue Pharmaceuticals is based in Wilson, NC and offers a diverse product line. The private company is committed to supporting collaborations to drive innovations in patient care while addressing the opioid addiction crisis. | Health Technology |
